Eric Haura
Associate Center Director, Clinical Science Moffitt Cancer Center
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficac
1:30 pm
• Uncovering factors within the tumor microenvironment which may result in non-responsiveness to
RAS-targeted therapies
• How do tissue specific interactions influence efficacy of RAS-targeting drugs?
• How do you successfully overcome or delay resistance to RAS-targeting therapies?
Wednesday 17th September 2025
Developing Multi-Omic Biomarker Strategies for Assessing Sensitivity of RASTargeting Drugs for More Efficacious Therapies
11:30 am
- Uncovering the impact of genomics on RAS inhibitor sensitivity
- Highlighting how transcriptional signatures may affect sensitivity to RAS targeting drugs
- Predicting RAS sensitivity through proteomic biomarkers and pathway analysis to advance more effective RAS-targeting drugs and combinations
